Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75

BACKGROUND: CD70 is an ideal target for antibody-based therapies because of its aberrant high expression in renal carcinomas and non-Hodgkin lymphomas and its highly restricted expression in normal tissues. The expression profiling of CD70 in carcinomas has been limited because of the lack of a CD70...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryan, M C, Kostner, H, Gordon, K A, Duniho, S, Sutherland, M K, Yu, C, Kim, K M, Nesterova, A, Anderson, M, McEarchern, J A, Law, C-L, Smith, L M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938259/
https://www.ncbi.nlm.nih.gov/pubmed/20664585
http://dx.doi.org/10.1038/sj.bjc.6605816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938259/
https://www.ncbi.nlm.nih.gov/pubmed/20664585
http://dx.doi.org/10.1038/sj.bjc.6605816

Ejemplares similares